We missed one! The FDA recently (back on January 27th) approved a new ORAL therapy, Orserdu (elacestrant) from Stemline Therapeutics, Inc., indicated for postmenopausal women
Remicade is one of the cornerstone therapies in the market racking up billions in annual sales. But J&J-Janssen didn’t appreciate the approvals of four biosimilars starting
Today we spotlight an article that details the leading healthcare services companies. While the information may be old news for many of you, it may be
Last week the FDA approved a new oral solution therapy, Daybue (trofinetide) from Acadia Pharmaceuticals Inc., for the treatment of Rett syndrome in adult and
The number of biosimilars launching in 2023 will spike as legal challenges around patent infringement are finally expiring. That will only exacerbate the problem of biosim
The article below should be a learning moment for the specialty pharmacy industry. It is all about going digital…. but it does not get lost in techno
This week the FDA approved a new ORAL specialty drug, Skyclarys (omaveloxolone) from Reata Pharmaceutical, indicated for the treatment of Friedreich’s Ataxia in adults and
The FDA recently approved a new antihemophilic factor (recombinant) for Hemophilia A, Altuviiio (Fc-VWFXTEN fusion protein-ehtl) from Sanofi. It was approved for prophylaxis, on-demand treatment of
The article below speaks to a variety of inefficiencies in Specialty Pharmacy Information Technology. What an opportunity to create a new acronym…. SPIT. The article makes the case that SPIT
Just about every specialty pharmacy has already obtained specialty pharmacy accreditation if they want to be a serious player in the SP market. The most serious
